Panacea Biotec Ltd secured a Letter of Award from UNICEF worth approximately Rs.78.24 Crore ($8.205 million). The contract involves supplying bivalent Oral Polio Vaccine during 2028.
Panacea Biotec joined the €11.1 million (₹120.90 Crore) EU-funded DENSTAR consortium. The 48-month project advances licensure of its DengiAll vaccine in sub-Saharan Africa.
Panacea Biotec Ltd secured a ₹20.79 Crore contract from the Central Medical Services Society (CMSS) to supply Diphtheria and Tetanus Vaccine (Td Vaccine). Deliveries will occur in several tranches between late 2026 and late 2028, providing steady revenue visibility for the company's vaccine segment.
Value
₹20.79 Cr
Execution
September / October 2026 till November / December 2028
